1Smith TJ. lntravitreal sustained-release ganciclovir[J]. Arch Ophthalmol,1992,110(2) :255.
2Kunou N, Ogura Y, Hashizoe M,et al. Controlled intraocular delivery of ganciclovir with use of biodegradable scleral implant in rabbits[ J]. Control Release, 1995,37( 1 -2) :143.
3Kimura H, Ogura I. A new vitral drug delivery system using an impantable biodegradable polymeric device [ J ]. Invest Ophthalmol Vis Sei, 1994,35(6) :2815.
6Paulsson M, Hagerstom H, Edsman K. Rheological Studies of the gelation of deacetylated gellan gum( Gelrite (r))in physiological conditions[ J]. Eur J Pharm Sci, 1999,9 (1):99.
7Carfors J, Edsman K, Petersson R, et al. Rheological evaluation of Gelrite in situ gels for ophthalmic use[ J]. Eur J Pharm Sci, 1995,6 (2):113.
8Matschke C, Isele U, Fahr A, et al. Sustainedrelease injectables formed in situ and their potential use for veterinary products [ J]. J Control Rel,2002,85 ( 1-3 ) : 1 - 15.
9Jeong B. New biodegradablepolymers for injectable drug delivery systems [ J ]. J Control release, 1999,62 ( 1 - 2 ) : 109 - 114.
10Hatefi A, Amsden B. Biodegradable injectable in situ forming drug delivery systems [ J ]. J Controlled Release,2002,80 ( 1 - 3 ) :9 - 28.
二级参考文献46
1Cohen S, Lobel E, Trevgoda A, et al. A novel in situ-forming ophthalmic drug delivery systems from alginates undergoing gelation in the eye [J] .J Controlled Release, 1997,44(2-3) :201.
2Gurny R, Boye T, lbrahim H. Ocular therapy with nanoparticulate systems for controlled drug delivery [J ]. J Controlled Release, 1985,2(3 ): 353.
3Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system [ J ]. J Controlled Release ,2001,73(2) :205.
4Lin HR, Sung KC. Carbopol/pluronic phase change solutions for ophthalmic drug delivery [J ]. J Controlled Release ,2000,69(3 ) :379.
5Yun MO,Choi HG,Jung JH,et al. Development of a thermo-reversible insulin liquid suppository with bioavailability enhancement [J]. Int J Pharm, 1999,189(2) : 137.
6Desai SD,Blanchard J. Evaluation of Pluronic F127 sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model [J ]. J Pharm Sci, 1998,87(10) : 1190.
7Shin SC, Cho CW, Oh IJ. Effect of non-ionic surfactants as permeation enhancers towards piroxicam from the poloxamer gel through rat skins [J]. Int J Pharm ,2001,222(2) : 199.
8Wei G, Xu H, Ding PT, et al. Thermosetting gels with modulated gelation temperature for ophthalmic use: rheological and gamma scintigraphic studies [ J ]. J Controlled Release, 2002,83 ( 1 ) : 65.
9Bromberg L,Orkisz M,Roos E, et al. Interpenetrating networks of poloxamer copolymers and poly (acrylic acid ) as vehicles in controlled drug delivery [ J ]. J Controlled Release, 1997,48 (2) :305.
10Jeong B,Bae YH, Lee DS, et al. Biodegradable block copolymer as injectable drug-delivery system [J ]. Nature, 1997, 388 (28) :860.
7OLANOW CW, OBESO JA, STOCCHI F. Drug insight : continu- ous dopaminergic stimulation in the treatment of Parkinson's dis- ease [ J ]. Nat Clin Pract Neurol,2006,2 ( 7 ) : 382 - 392.
8OLANOW CW, OBESO JA, STOCCHI F. Continuous dopamine- receptor treatment of Parkinson's disease: scientific rationale and clinical implications[ J]. Lancet Neurol,2006,5 ( 8 ) :677 - 687.
9NYHOLM D. The rationale for continuous dopamincrgic stimula- tion in advanced Parklnson's disease [ J ]. Parkinsonism Relat Disord ,2007,13 (Suppl) : $13 - S17.
10CHEUNG RY,KUBA R,RHAUT AM. A new approach to the in vivo and in vitro investigation of drug release from loco regionally delivered microspheres [ J ]. J Control Release, 2004,100 ( 1 ) : 121 - 133.
